Sign In
Buy REGN
$618.95
+16.03 (+2.66%)
At Close: Jun 03, 2026
Shareholders that lost money on Regeneron Pharmaceuticals, Inc. (REGN) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
07:15pm, Wednesday, 05'th Mar 2025
NEW YORK CITY, NY / ACCESS Newswire / March 5, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the fed
Investors can contact the law firm at no cost to learn more about recovering their losses
NEW YORK, NY / ACCESS Newswire / March 5, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal
NEW YORK, NY / ACCESS Newswire / March 5, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) between Novem
NEW YORK, NY / ACCESS Newswire / March 5, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal
March 10, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against REGN
11:30am, Wednesday, 05'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 5, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals
11:03am, Wednesday, 05'th Mar 2025
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Regeneron To Contact Him Directly To Discuss Their Options If you purchased or acquir
Inclusion Body Myositis Pipeline Market Landscape Report 2025 Featuring Abcuro, Regeneron Pharmaceuticals, and Vandria
10:39am, Wednesday, 05'th Mar 2025
Dublin, March 05, 2025 (GLOBE NEWSWIRE) -- The "Inclusion Body Myositis - Pipeline Insight, 2025" report has been added to ResearchAndMarkets.com's offering. This report offers in-depth insights into
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN
10:00am, Wednesday, 05'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 5, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ:REGN)
Levi & Korsinsky Reminds Regeneron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN
09:00am, Wednesday, 05'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 5, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal
PHILADELPHIA , March 5, 2025 /PRNewswire/ -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Com
NEW YORK, NY / ACCESS Newswire / March 5, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal
REGN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Stockholders of Regeneron Therapeutics, Inc. to Contact the Firm Today!
07:00am, Wednesday, 05'th Mar 2025
NEW YORK CITY, NY / ACCESS Newswire / March 5, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Regene
Shareholders of Regeneron Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before March 10, 2025 to Discuss Your Rights – REGN
08:00pm, Tuesday, 04'th Mar 2025
NEW YORK, NY / ACCESS Newswire / March 4, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the federal
NEW YORK, NY / ACCESS Newswire / March 4, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) between Novem
